Alcami Corporation, a contract development and manufacturing organization (CDMO), has completed the acquisition of Pacific Pharmaceutical Services (PPS), a preferred provider of cGMP pharma storage and services.

“The Pacific Pharmaceutical Services acquisition is part of our highly intentional strategy to supercharge the capabilities of our pharma storage and services business with locations that best serve biotech and pharma clients across the country,” said Bill Humphries, CEO, Alcami. “With its strategic West Coast location, we can better address bicoastal market needs, improve material safeguarding from natural disasters with multi-location facilities and support multi-center clinical trials. Adding PPS to the Alcami family cements our status as the U.S. CDMO for West Coast projects as we continue to focus on the stability and security that matters most in storage of pre-clinical and clinical materials.”

In addition to the acquisition of PPS, Alcami is expanding its central North Carolina pharma storage and service footprint with the opening of a new 65,000 square foot facility co-located near the Research Triangle Park’s biotech and pharma hub. Combined with the acquisition, this additional expansion underscores Alcami’s focus on its pharma storage and services business.

PPS offers controlled storage and material management solutions—controlled temperature storage from room temperature down to cryo temperatures and material aliquoting—as well as clinical labeling and support for most development lifecycle stages spanning from pre-clinical to early clinical trials. PPS also provides clinical distribution and material management across various conditions. PPS founder Scott Chadwick will continue with the company in the role of general manager and site head.

“I’m proud of the business we built and look forward to partnering with Alcami,” said Chadwick. “Combining forces enables us to offer clients even more solutions with the same agile, flexible approach that continues to make us successful.”

Alcami’s service offerings range from analytical development and testing to full drug product development and manufacturing of both sterile fill-finish and oral solid dose. The CDMO’s client base will have access to PPS’ West Coast cGMP pharma storage capacity and support services.